CSL to Pay Up to $1.6 Billion to Develop Rare Disease Drug; Shares Rise

3-line summary

• CSL agreed to pay up to $1.6 billion to develop a rare disease drug, and its shares rose on the news, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.